Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... July 9 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... improvement in rheumatoid arthritis (RA) patients in the recently completed ... up to 6 months. The groups treated with 100 ... qd (once a day) reported higher ACR 20, ACR 50, ...
... , THOUSAND OAKS, Calif., July 7 Amgen (Nasdaq: ... Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic ... patients with advanced breast cancer met its primary and ... Superiority was demonstrated for both delaying the time ...
Cached Medicine Technology:Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 2Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 3Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 5Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 6Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of ... unification of their Healthy Home mission with the HOPE Movement of EvolvHealth. In what ... of both companies have agreed to join their missions of purpose together to change ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec released a security ... have been behind the attack on Anthem Inc. which resulted in one of the ... hole attacks and spear phishing campaigns. , For Joe Caruso, founder and ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic ... very first small business donation to kick off the campaign for healing and Well-Being. ... legacy includes a complete line of raw, organic hair care products, as well as ...
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... ... 31, 2015 , ... Ticket Down is a reputable source of authentic tickets for the ... Fans of every genre of music will have an act they are excited to ... the festival, the following artists will perform: Sam Smith, Coldplay, Kenny Chesney, The Who, ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:March4thforWellBeing Foundation Kickoff 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3
... health committee is all set to tighten the screws ... days of public hearing starting on Jan 23, is ... will make submissions before the committee. ,Under ... the sponsorship of sports and other popular events by ...
... way that primary care is organized, delivered, financed, and ... were released today by the American College of Physicians ... the Nation's Health Care. ,The U.S. health ... medicine, the ACP reported in its January 2006 State ...
... viral culture system, which makes way for a better ... replication of virus// (isolated from patient) in non-transformed hepatocytes. ... in transformed cell lines. ,The study report ... transfected and serum-infected cultured human fetal hepatocytes,’ appears in ...
... been accomplished by people who have kept on trying when there ... ,A groundbreaking venture has been ... cancer-treatment, are mass-produced in the egg white of a certain breed ... is one of the leading causes of death in the world. ...
... known as microchimerism has been known for some years, that ... pregnancy, and that these may live on for many// years, ... still unclear as to whether the presence of such cells ... team has looked for maternal cells in children with type ...
... findings that point to yet another benefit of statins; improving ... prescribed for heart patients. They work by lowering the levels ... in arteries. ,The drugs have also been shown ... of heart disease from having a heart attack or stroke. ...
Cached Medicine News:Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 2Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 3Health News:A Breakthrough in the Study of Hepatitis C 2Health News:'Hen Factories' To Synthesize Cancer Drugs 2Health News:Stem Cells Passed From Mother to Child Live On and Make Insulin 2Health News:Statins Aid Survival in Lung Patients, Say Experts 2
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Flexible vinyl with a rigid bite block. Guedel-style with three internal channels. Individually packaged, 48 per case. Latex Free....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: